{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T13:58:16Z","timestamp":1793973496430,"version":"4.8.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,2,26]],"date-time":"2014-02-26T00:00:00Z","timestamp":1393372800000},"content-version":"vor","delay-in-days":25,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1053\/j.seminoncol.2014.01.001","type":"journal-article","created":{"date-parts":[[2014,1,9]],"date-time":"2014-01-09T20:30:27Z","timestamp":1389299427000},"page":"S1-S16","source":"Crossref","is-referenced-by-count":121,"special_numbering":"S2","title":["Management of Sorafenib-Related Adverse Events: A Clinician\u2019s Perspective"],"prefix":"10.1053","volume":"41","author":[{"given":"Marcia S.","family":"Brose","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine T.","family":"Frenette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Keefe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey M.","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2014.01.001_bib1","year":"2012"},{"key":"10.1053\/j.seminoncol.2014.01.001_bib2","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2014.01.001_bib3","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminoncol.2014.01.001_bib4","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.ejca.2011.12.006","article-title":"Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial","volume":"48","author":"Cheng","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.seminoncol.2014.01.001_bib5","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2014.01.001_bib6","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2008.19.5511","article-title":"Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial","volume":"27","author":"Escudier","year":"2009","journal-title":"J Clin Oncol"},{"issue":"Suppl 8","key":"10.1053\/j.seminoncol.2014.01.001_bib7","first-page":"691PD","article-title":"An open-labeled phase 2 study evaluating the safety and efficacy of sorafenib in metastatic advanced thyroid cancer [abstract]","volume":"19","author":"Ahmed","year":"2008","journal-title":"Ann Oncol (Meeting Abstracts)"},{"key":"10.1053\/j.seminoncol.2014.01.001_bib8","article-title":"Completion of a phase II study of sorafenib for advanced thyroid cancer [abstract]","volume":"7","author":"Brose","year":"2009","journal-title":"Eur J Cancer Suppl (Meeting Abstracts)"},{"key":"10.1053\/j.seminoncol.2014.01.001_bib9","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1200\/JCO.2008.18.2717","article-title":"Phase II trial of sorafenib in metastatic thyroid cancer","volume":"27","author":"Kloos","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2014.01.001_bib10","doi-asserted-by":"crossref","first-page":"4714","DOI":"10.1200\/JCO.2008.16.3279","article-title":"Phase II trial of sorafenib in advanced thyroid cancer","volume":"26","author":"Gupta-Abramson","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2014.01.001_bib11","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1186\/1471-2407-11-349","volume":"11","author":"Brose","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1053\/j.seminoncol.2014.01.001_bib12","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1200\/jco.2013.31.18_suppl.4","article-title":"Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase III DECISION trial [abstract]","volume":"31","author":"Brose","year":"2013","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1053\/j.seminoncol.2014.01.001_bib13","first-page":"29","article-title":"Design of RESILIENCE: a phase (Ph) III trial comparing capecitabine (CAP) in combination with sorafenib (SOR) or placebo (PL) for treatment (tx) of locally advanced (adv) or metastatic HER2-negative breast cancer (BC) [abstract]","author":"Baselga","year":"2011","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1053\/j.seminoncol.2014.01.001_bib14","doi-asserted-by":"crossref","first-page":"4126","DOI":"10.1200\/jco.2013.31.15_suppl.4126","article-title":"Final analysis of GIDEON (Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma [HCC] and of its treatment with sorafenib [Sor]) in>3000 Sor-treated patients (pts): clinical findings in pts with liver dysfunction [abstract]","volume":"31","author":"Marrero","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2014.01.001_bib15","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1365-2230.2011.04060.x","article-title":"Meta-analysis of dermatological toxicities associated with sorafenib","volume":"36","author":"Zhang","year":"2011","journal-title":"Clin Exp Dermatol"},{"key":"10.1053\/j.seminoncol.2014.01.001_bib16","unstructured":"National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Hepatobiliary Cancer. Version 2.2013. http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp#site. Accessed January 22, 2014."},{"key":"10.1053\/j.seminoncol.2014.01.001_bib17","unstructured":"National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Kidney Cancer. Version 2.2014. http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp#site. Accessed January 22, 2014."},{"key":"10.1053\/j.seminoncol.2014.01.001_bib18","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s10238-007-0145-8","article-title":"Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib","volume":"7","author":"Porta","year":"2007","journal-title":"Clin Exp Med"},{"key":"10.1053\/j.seminoncol.2014.01.001_bib19","doi-asserted-by":"crossref","first-page":"4008","DOI":"10.1200\/jco.2012.30.15_suppl.4008","article-title":"A randomized controlled phase II study of the prophylactic effect of urea-based cream on the hand-foot skin reaction associated with sorafenib in advanced hepatocellular carcinoma [abstract]","volume":"30","author":"Ren","year":"2012","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1053\/j.seminoncol.2014.01.001_bib20","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1634\/theoncologist.2008-0237","article-title":"Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs)","volume":"14","author":"Anderson","year":"2009","journal-title":"Oncologist"},{"key":"10.1053\/j.seminoncol.2014.01.001_bib21","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1001\/archderm.144.7.886","article-title":"Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor","volume":"144","author":"Autier","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1053\/j.seminoncol.2014.01.001_bib22","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1097\/MCG.0b013e3181f68e83","article-title":"Clinical management and case reports for the treatment of hepatocellular carcinoma with sorafenib","volume":"45","author":"Frenette","year":"2011","journal-title":"J Clin Gastroenterol"},{"key":"10.1053\/j.seminoncol.2014.01.001_bib23","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1093\/annonc\/mdn389","article-title":"Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib","volume":"19","author":"Lacouture","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2014.01.001_bib24","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.suponc.2010.12.007","article-title":"Management of tyrosine kinase inhibitor-induced hand-foot skin reaction: viewpoints from the medical oncologist, dermatologist, and oncology nurse","volume":"9","author":"Manchen","year":"2011","journal-title":"J Support Oncol"},{"key":"10.1053\/j.seminoncol.2014.01.001_bib25","doi-asserted-by":"crossref","first-page":"7749","DOI":"10.1158\/1078-0432.CCR-09-1190","article-title":"Sorafenib-related hand-foot skin reaction improves, not worsens, with continued treatment","volume":"15","author":"Flaherty","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2014.01.001_bib26","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1016\/j.ejca.2010.06.121","article-title":"Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET","volume":"46","author":"Hutson","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.seminoncol.2014.01.001_bib27","doi-asserted-by":"crossref","first-page":"e17009","DOI":"10.1200\/jco.2013.31.15_suppl.e17009","article-title":"Timing and severity of skin-related adverse events in a phase II trial of sorafenib (BAY43-9006) in patients with advanced thyroid cancer [abstract]","volume":"31","author":"Terry","year":"2013","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1053\/j.seminoncol.2014.01.001_bib28","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1634\/theoncologist.2008-0131","article-title":"Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib","volume":"13","author":"Lacouture","year":"2008","journal-title":"Oncologist"},{"key":"10.1053\/j.seminoncol.2014.01.001_bib29","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/S1548-5315(11)70751-3","article-title":"Managing the side effects of sorafenib and sunitinib","volume":"3","author":"Wood","year":"2006","journal-title":"Comm Oncol"},{"key":"10.1053\/j.seminoncol.2014.01.001_bib30","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1634\/theoncologist.10-5-345","article-title":"HER1\/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1\/EGFR inhibitor rash management forum","volume":"10","author":"Perez-Soler","year":"2005","journal-title":"Oncologist"},{"key":"10.1053\/j.seminoncol.2014.01.001_bib31","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1200\/JCO.2004.04.132","article-title":"Recommended guidelines for the treatment of cancer treatment-induced diarrhea","volume":"22","author":"Benson","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2014.01.001_bib32","unstructured":"National Cancer Institute. Nutrition in cancer care (PDQ): diarrhea. October 24, 2013. http:\/\/www.cancer.gov\/cancertopics\/pdq\/supportivecare\/nutrition\/HealthProfessional\/page4#Section_148. Accessed January 22, 2014."},{"key":"10.1053\/j.seminoncol.2014.01.001_bib33","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3747\/co.2007.96","article-title":"Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: a consensus statement by the Canadian Working Group on Chemotherapy-Induced Diarrhea","volume":"14","author":"Maroun","year":"2007","journal-title":"Curr Oncol"},{"key":"10.1053\/j.seminoncol.2014.01.001_bib34","unstructured":"National Cancer Institute. Gastrointestinal complications (PDQ): diarrhea. September 10, 2013. http:\/\/www.cancer.gov\/cancertopics\/pdq\/supportivecare\/gastrointestinalcomplications\/HealthProfessional\/page5. Accessed January 22, 2014."},{"key":"10.1053\/j.seminoncol.2014.01.001_bib35","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.critrevonc.2010.03.006","article-title":"Experience with sorafenib and adverse event management","volume":"78","author":"Bellmunt","year":"2011","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1053\/j.seminoncol.2014.01.001_bib36","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1188\/07.CJON.649-656","article-title":"Sorafenib: a promising new targeted therapy for renal cell carcinoma","volume":"11","author":"Wood","year":"2007","journal-title":"Clin J Oncol Nurs"},{"key":"10.1053\/j.seminoncol.2014.01.001_bib37","year":"2013"},{"issue":"suppl 5","key":"10.1053\/j.seminoncol.2014.01.001_bib38","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.3949\/ccjm.70.Suppl_5.S51","article-title":"Profile and assessment of GERD pharmacotherapy","volume":"70","author":"Maton","year":"2003","journal-title":"Cleve Clin J Med"},{"key":"10.1053\/j.seminoncol.2014.01.001_bib39","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/ajg.2012.444","article-title":"Guidelines for the diagnosis and management of gastroesophageal reflux disease","volume":"108","author":"Katz","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.seminoncol.2014.01.001_bib40","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1111\/j.1572-0241.2001.03964.x","article-title":"Practice Parameters Committee of the American College of Gastroenterology. Hepatic encephalopathy","volume":"96","author":"Blei","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.seminoncol.2014.01.001_bib41","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00520-004-0740-0","article-title":"Fatigue patterns and correlates in male liver cancer patients receiving transcatheter hepatic arterial chemoembolization","volume":"13","author":"Shun","year":"2005","journal-title":"Support Care Cancer"},{"key":"10.1053\/j.seminoncol.2014.01.001_bib42","unstructured":"National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Cancer-related fatigue. Version 1.2014. http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp. Accessed January 22, 2014."},{"key":"10.1053\/j.seminoncol.2014.01.001_bib43","doi-asserted-by":"crossref","first-page":"e15564","DOI":"10.1200\/jco.2013.31.15_suppl.e15564","article-title":"Increase in blood pressure with sorafenib exposure: renal cell carcinoma (RCC) versus other solid tumors [abstract]","volume":"31","author":"Shah","year":"2013","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1053\/j.seminoncol.2014.01.001_bib44","first-page":"675","article-title":"Hyponatraemia in patients with cirrhosis","volume":"76","author":"Papadakis","year":"1990","journal-title":"Q J Med"},{"key":"10.1053\/j.seminoncol.2014.01.001_bib45","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/S0140-6736(08)60383-9","article-title":"Liver cirrhosis","volume":"371","author":"Schuppan","year":"2008","journal-title":"Lancet"},{"key":"10.1053\/j.seminoncol.2014.01.001_bib46","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1200\/JCO.2005.03.6723","article-title":"Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma","volume":"24","author":"Ratain","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2014.01.001_bib47","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1200\/JCO.2009.27.2757","article-title":"Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials","volume":"28","author":"Choueiri","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2014.01.001_bib48","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1200\/jco.2012.30.15_suppl.4500","article-title":"Cardiac safety analysis for a phase III trial of sunitinib (SU) or sorafenib (SO) or placebo (PLC) in patients (pts) with resected renal cell carcinoma (RCC) [abstract]","volume":"30","author":"Haas","year":"2012","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1053\/j.seminoncol.2014.01.001_bib49","unstructured":"Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, 2004. http:\/\/www.nhlbi.nih.gov\/guidelines\/hypertension\/jnc7full.htm. Accessed January 22, 2014."},{"key":"10.1053\/j.seminoncol.2014.01.001_bib50","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/hep.21941","article-title":"Platelet count is not a predictor of the presence or development of gastroesophageal varices in cirrhosis","volume":"47","author":"Qamar","year":"2008","journal-title":"Hepatology"},{"key":"10.1053\/j.seminoncol.2014.01.001_bib51","doi-asserted-by":"crossref","first-page":"e16978","DOI":"10.1371\/journal.pone.0016978","article-title":"Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib","volume":"6","author":"Coriat","year":"2011","journal-title":"PLoS One"},{"key":"10.1053\/j.seminoncol.2014.01.001_bib52","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.3748\/wjg.v18.i11.1166","article-title":"Treatment of portal hypertension","volume":"18","author":"Bari","year":"2012","journal-title":"World J Gastroenterol"},{"key":"10.1053\/j.seminoncol.2014.01.001_bib53","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1067\/moe.2000.105713","article-title":"Randomized clinical trial of the effectiveness of 3 commonly used mouthwashes to treat chemotherapy-induced mucositis","volume":"90","author":"Dodd","year":"2000","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"10.1053\/j.seminoncol.2014.01.001_bib54","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1188\/08.CJON.141-152","article-title":"Putting evidence into practice: evidence-based interventions for the management of oral mucositis","volume":"12","author":"Harris","year":"2008","journal-title":"Clin J Oncol Nurs"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775414000025?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775414000025?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T00:20:23Z","timestamp":1597364423000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775414000025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":54,"alternative-id":["S0093775414000025"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2014.01.001","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]}}}